First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis
Authors
Keywords
-
Journal
ADVANCES IN THERAPY
Volume 38, Issue 5, Pages 2447-2457
Publisher
Springer Science and Business Media LLC
Online
2021-04-06
DOI
10.1007/s12325-021-01734-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer
- (2020) Xiuhua Weng et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
- (2020) Dong Ding et al. ADVANCES IN THERAPY
- Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer
- (2020) Shen Lin et al. International Journal of Clinical Pharmacy
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
- (2020) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer
- (2019) Kexun Zhou et al. LUNG CANCER
- Cancer treatment and survivorship statistics, 2019
- (2019) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis
- (2019) XiaoMin Wan et al. CANCER
- Cost–effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA
- (2019) Min Huang et al. Immunotherapy
- Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater
- (2019) Longjiang She et al. LUNG CANCER
- Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer
- (2018) Mina Georgieva et al. LUNG CANCER
- Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
- (2017) Min Huang et al. PHARMACOECONOMICS
- Advances in the Treatment of Non–small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab
- (2016) Konstantinos Leventakos et al. BIODRUGS
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Improved curve fits to summary survival data: application to economic evaluation of health technologies
- (2011) Martin W Hoyle et al. BMC Medical Research Methodology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now